SLP.US Simulations Plus Inc

Healthcare Health Care Technology USA Stocks
18.50 USD
Close of Nov 18, 2026
11.09 21.01
Market cap
USD 374M
P/E
46.3x
P/B
2.69x
ROE
8.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.

Is SLP.US undervalued?

Graham number
Price18.50
Graham value7.87
Premium135.2%

SLP.US trades 135.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Simulations Plus Inc fundamental analysis

No fundamental analysis for Simulations Plus Inc yet.

Simulations Plus Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides…

Full company profile